Hemophilia hematology > hemophilia key points hemophilia a and b are genetically inherited deficiencies of coagulation factors viii and ix, respectively; these deficiencies are most commonly inherited in a x-linked recessive fashion patients present with 'factor-type bleeding,' which results from an inability to form a fibrin clot; these bleeding events include hemarthroses, mucosal bleeding, and intracranial bleeding the current standard of treatment is recombinant coagulation factors, or fresh frozen plasma (ffp) in emergent situations urgent action: for acute bleeding in persons in whom a coagulation disorder is suspected but not confirmed: urgent admission for transfusion of blood products patients with active life-threatening bleeding who are suspected of having a congenital bleeding disorder can be supported with ffp, 15 ml/kg, or cryoprecipitate while diagnostic studies are being done the risk of viral transmission of hepatitis b or c or hiv must be considered for acute bleeding in known hemophiliac patients: significant bleeding requires urgent admission for transfusion factor viii or ix concentrate infusion is urgently needed. buy viagra online buy cheap viagra cheap generic viagra nationalityinworldhistory.net/bsh-viagra-cheap-online-cs/ floridalighttacklecharters.com/thq-secure-canadian-pharmacy-online-cheap-viagra-iq/ buy cheap viagra buy viagra buy generic viagra viagra online cheap viagra canada
The quantity required depends on the site and nature of the bleeding. Usually, raising clotting factor levels to 30% is sufficient to control hemorrhage. Major surgery or life-threatening bleeding requires the level to be raised to 100% and then maintained at 30% to 50% for 2 weeks to prevent secondary hemorrhage desmopressin acetate 0. 3 î¼g/kg may be used in mild hemophilia a aminocaproic acid (eaca) 4 g orally every 4 hours can be given as an adjunct treatment for persistent bleeding that is unresponsive to factor viii concentrate or desmopressin in hemophilia a, but consider the presence of inhibitor that may require use of high-dose factor viii or factor viia for acute hemarthroses: prompt treatment is essential. Patients can be taught to give replacement therapy at home refer for urgent orthopedic assessment, as aspiration may be considered if the patient is not responding to.